AstraZeneca and Innovative Cellular Therapeutics Report Clinical Data in Solid Tumors; AACR 2023 Analysis 3
Here is a brief preview of this blast: AACR 2023 Analysis 3: AstraZeneca (AZ), and Innovative Cellular Therapeutics (ICT) presented clinical updates on their CAR-T assets for solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered: